Today's MSD is a global healthcare leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MSD’S ALZHEIMER’S DRUG FAILURE UNDERMINES POTENTIAL TREATMENT PATHWAY

Pharmafocus | February 15, 2017

news image

MSD, known as Merck in North America, has announced that it has been forced to cancel a Phase 2/3 trial studying the potential therapeutic effects of verubecestat in Alzheimer’s patients. The failure of the drug to show efficacy draws into question how amyloid plaques are being targeted and whether this is now a viable target for treatment. The trial was stopped by an independent panel of experts that concluded that there was “virtually no chance of finding a positive clinical effect”. The ne...

Read More

MSD INVESTMENT CONFIRMS THRIVING BIOPHARMACEUTICAL HUB

European Pharmaceutical Review | June 08, 2017

news image

BioPharmaChem Ireland, the Ibec group that represents business in the sector, said the announcement of MSD to invest €280 million in Ireland over the next three years bolsters the country’s status as a thriving hub for the biopharmaceutical sector....

Read More

MSD’S KEYTRUDA BACKED FOR BLADDER CANCER

MSD | July 25, 2017

news image

European regulators have backed expanding approval of MSD’s immunotherapy Keytruda to include the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. Clearance of the drug is recommended for adult patients with the condition who have received prior platinum-containing chemotherapy, as well as those not eligible for cisplatin-containing chemotherapy. “There is significant need for new options that address the treatment gaps for patients in Europe with local...

Read More

MSD PULLS PLUG ON CHOLESTEROL DRUG ANACETRAPIB

MSD | October 12, 2017

news image

MSD has decided to pull the plug on its late-stage cholesterol drug anacetrapib after a lacklustre performance in clinical trials. The company said it would not file for approval of the investigational cholesteryl ester transfer protein (CETP) inhibitor on the back of a review of its clinical profile that included discussions with external experts....

Read More
news image

MSD’S ALZHEIMER’S DRUG FAILURE UNDERMINES POTENTIAL TREATMENT PATHWAY

Pharmafocus | February 15, 2017

MSD, known as Merck in North America, has announced that it has been forced to cancel a Phase 2/3 trial studying the potential therapeutic effects of verubecestat in Alzheimer’s patients. The failure of the drug to show efficacy draws into question how amyloid plaques are being targeted and whether this is now a viable target for treatment. The trial was stopped by an independent panel of experts that concluded that there was “virtually no chance of finding a positive clinical effect”. The ne...

Read More
news image

MSD INVESTMENT CONFIRMS THRIVING BIOPHARMACEUTICAL HUB

European Pharmaceutical Review | June 08, 2017

BioPharmaChem Ireland, the Ibec group that represents business in the sector, said the announcement of MSD to invest €280 million in Ireland over the next three years bolsters the country’s status as a thriving hub for the biopharmaceutical sector....

Read More
news image

MSD’S KEYTRUDA BACKED FOR BLADDER CANCER

MSD | July 25, 2017

European regulators have backed expanding approval of MSD’s immunotherapy Keytruda to include the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. Clearance of the drug is recommended for adult patients with the condition who have received prior platinum-containing chemotherapy, as well as those not eligible for cisplatin-containing chemotherapy. “There is significant need for new options that address the treatment gaps for patients in Europe with local...

Read More
news image

MSD PULLS PLUG ON CHOLESTEROL DRUG ANACETRAPIB

MSD | October 12, 2017

MSD has decided to pull the plug on its late-stage cholesterol drug anacetrapib after a lacklustre performance in clinical trials. The company said it would not file for approval of the investigational cholesteryl ester transfer protein (CETP) inhibitor on the back of a review of its clinical profile that included discussions with external experts....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us